Related Experiment Video
Updated: Feb 1, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
[Lung cancer screening]
1Univ. Klinik für Radiologie und Nuklearmedizin, Medizinische Universität Wien, Allgemeines Krankenhaus Wien, Währingergürtel 18-20, 1090, Wien, Österreich. helmut.prosch@meduniwien.ac.at.
Clinical/Methodical Issue:
The National Lung Screening Trial (NLST) in 2011 was able to prove for the first time that screening with a low-dose CT can reduce lung carcinoma mortality by 20%. Despite the positive outcome of the NLST, there is-unlike in the USA-currently no systematic lung cancer screening in Europe. This is partly because several significantly smaller screening studies in Europe failed to show any improvement in lung cancer mortality.
Standard Radiological Methods:
On the other hand, Europe's healthcare systems differ substantially from those in the United States, so that a direct transfer of US experience to Europe is not possible. For this reason, guidelines for lung cancer screening must be developed in the individual European countries to ensure that lung cancer mortality can be reduced by means of a quality-assured and cost-effective lung cancer screening.
Practical Recommendations:
The experience and the expected results of the European screening studies can provide valuable help for these purposes.
Related Concept Videos
01:47Lung Capacity
01:13Pleura of the Lungs
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
01:17Gross Anatomy of the Lungs
02:18Cancer
02:12What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...